The FDA has tentatively approved Teva’s ProAir RespiClick albuterol dry powder inhaler as of March 5, 2015. Teva filed an NDA for an albuterol “MDPI” (multi-dose dry powder inhaler) for the treatment of asthma in July 2014. At the time, it referred to the product as “ProAir Spiromax.”
View the FDA approval history.
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
March 10-March 11: MVIC Spring Training 2026, Lund, Sweden
March 11: RespireX, Hinxton, UK
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
